Peripheral endothelial progenitor cells (CD133+) for therapeutic vasculogenesis in a patient with critical limb ischemia. : One year follow-up

We present a patient with critical limb ischemia who was successfully treated with the injection of autologous peripheral blood (PB) CD133+ purified stem celly (SC) into the gastrocnemius muscle. No serious adverse events related to G-CST administration, mononuclear cells harvest or CD133+ SC administration was observed. After 17 months of follow-up, our patient hay experienced limb salvage, symptomatic relief and Junctional improvement. Moreover, we have observed the appearance of flow in the right posterior tibial artery that was absent before the procedure. To our knowledge, this is the first case of critical limb ischemia treated with PB CD133+ SC.